at Nasdaq.com (Dec 15, 2014)
StemCells (STEM +0.5%) has been awarded a U.S. Patent entitled "Liver engrafting cells, assays,...
StemCells (STEM +0.5%) has been awarded a U.S. Patent entitled "Liver engrafting cells, assays, and uses thereof," which broadly covers purified populations of human liver cells, including its own human liver engrafting cells. The research centers on STEM's hLEC technologies to develop the expandable capabilities of liver cell transplantation, which could potentially address many of the shortcomings of whole liver transplantation.
From other sites
at MarketWatch.com (Feb 12, 2013)
at Fox Business (Aug 30, 2012)
at MarketWatch.com (Jul 5, 2011)
at MarketWatch.com (Jun 16, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs